Jim Tananbaum founded Foresite Capital in 2011 and serves as the company’s CEO. Foresite Capital is a privately held equity and healthcare company and its primary area of specialization is identifying emerging health care leaders in the industry. Jim also takes part in several medical investments like Juno Therapeutics and Intarcia Therapeutics which have enabled him to be named on the Midas List of Top Tech Investors by Forbes for three consecutive years. He also invests on Aimmune and Puma Biotechnology which is an immunotherapy treatment for food allergies.
About Foresite Capital
Foresite Capital is headquartered in San Francisco with an additional office in the New York City. Foresite Capital offers emerging providers with disruptive products in the healthcare industry growth capital, in the public and private markets. The largest and latest investment of Foresite Capital is Intarcia, a type II diabetes implant used to assist patients in controlling their weight and diabetes levels.
About Jim Tananbaum
According to Wired, apart from being a founding Chief Executive of Foresite Capital, Jim has successfully led 21 healthcare investments including Amira Pharmaceuticals which was acquired by Amerigroup & Jazz Pharmaceuticals. Prior to that, Dr. Tananbaum founded GelTex Pharmaceuticals in 1998 where he held several management positions. GelTex Pharmaceuticals was acquired by Theravance and Genzyme for $1.6 billion with its lead drug Renzela generating a 200 million dollar revenue rate.
Tananbaum has over 25years experience in the health care industry. He has also served as a founding partner at Prospect Venture Partners and Sierra Ventures. Jim holds an M.B.A and M.D from Harvard Business School and Harvard Medical School respectively. Furthermore, Jim holds a B.S. and B.S.E.E. and B.S from Yale University where he majored in electrical and science engineering. Tananbaum also graduated with M.S. from the Massachusetts Institute of Technology.
Jim Tananbaum has served on visiting committees and advisory boards for the MIT HST program at Harvard. Apart from that, he has been mentored by various leading academicians such as Roy Vagelos from Theravance, Rick Levin from Yale, and George Whitesides from Harvard University. As a result, he has established long-term productive relationships academicians to develop new insights in the healthcare sector.